Research library / GLP-1 drugs

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

A Lincoff, K Brown-Frandsen, H Colhoun, J Deanfield, S Emerson, S Esbjerg et al.. New England Journal of Medicine. 2023.

Published 2026-10-15Sources checked 2026-10-151 sourceEverstack research teamHow we work

In plain language

SELECT: weekly semaglutide 2.4 mg reduced major cardiovascular events in people with obesity and heart disease without diabetes.

Limits

Prescription drug; manufacturer funded.

Source

doi.org/10.1056/NEJMoa2307563 · PubMed 37952131

Summary written by Everstack from the published abstract. Verified against Crossref on 2026-10-15. The authors do not endorse Everstack.